OTCM
IPCIQ
Market cap0kUSD
Feb 21, Last price
0.00USD
Name
Intellipharmaceutics International Inc
Chart & Performance
Profile
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
IPO date
Jul 22, 1999
Employees
11
Domiciled in
CA
Incorporated in
CA
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|
2022‑11 | 2021‑11 | 2020‑11 | 2019‑11 | 2019‑02 | 2017‑11 | 2016‑11 | 2015‑11 | |
Income | ||||||||
Revenues | 66 0.00% | |||||||
Cost of revenue | 2,149 | |||||||
Unusual Expense (Income) | ||||||||
NOPBT | (2,083) | |||||||
NOPBT Margin | ||||||||
Operating Taxes | 5 | |||||||
Tax Rate | ||||||||
NOPAT | (2,089) | |||||||
Net income | (2,892) 0.00% | |||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
Debt | ||||||||
Debt current | 2,326 | |||||||
Long-term debt | 165 | |||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | 2,408 | |||||||
Cash flow | ||||||||
Cash from operating activities | (1,388) | |||||||
CAPEX | ||||||||
Cash from investing activities | 500 | |||||||
Cash from financing activities | 200 | |||||||
FCF | (5,882) | |||||||
Balance | ||||||||
Cash | 84 | |||||||
Long term investments | ||||||||
Excess cash | 80 | |||||||
Stockholders' equity | (55,674) | |||||||
Invested Capital | 51,188 | |||||||
ROIC | ||||||||
ROCE | 46.44% | |||||||
EV | ||||||||
Common stock shares outstanding | 33,093 | |||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | (1,877) | |||||||
EV/EBITDA | ||||||||
Interest | 292 | |||||||
Interest/NOPBT |